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Abstract
Despite the marked advances in research on insulin resistance (IR) in humans and animal models
of insulin resistance, the mechanisms underlying high salt-induced insulin resistance remain unclear.
Insulin resistance is a multifactorial disease with both genetic and environmental factors (such as
high salt) involved in its pathogenesis. High salt triggers insulin resistance in genetically susceptible
patients and animal models of insulin resistance. One of the mechanisms by which high salt might
precipitate insulin resistance is through its ability to enhance an oxidative stress-induced
inflammatory response that disrupts the insulin signaling pathway. The aim of this hypothesis is to
discuss two complementary approaches to find out how high salt might interact with genetic
defects along the insulin signaling and inflammatory pathways to predispose to insulin resistance in
a genetically susceptible model of insulin resistance. The first approach will consist of examining
variations in genes involved in the insulin signaling pathway in the Dahl S rat (an animal model of
insulin resistance and salt-sensitivity) and the Dahl R rat (an animal model of insulin sensitivity and
salt-resistance), and the putative cellular mechanisms responsible for the development of insulin
resistance. The second approach will consist of studying the over-expressed genes along the
inflammatory pathway whose respective activation might be predictive of high salt-induced insulin
resistance in Dahl S rats.
Variations in genes encoding the insulin receptor substrates -1 and/or -2 (IRS-1, -2) and/or genes
encoding the glucose transporter (GLUTs) proteins have been found in patients with insulin
resistance. To better understand the combined contribution of excessive salt and genetic defects
to the etiology of the disease, it is essential to investigate the following question:
Question 1: Do variations in genes encoding the IRS -1 and -2 and/or genes encoding the GLUTs
proteins predict high salt-induced insulin resistance in Dahl S rats?
A significant amount of evidence suggested that salt-induced oxidative stress might predict an
inflammatory response that upregulates mediators of inflammation such as the nuclear factor-
kappa B (NF-kappa B), the tumor necrosis factor-alpha (TNF-α) and the c-Jun Terminal Kinase
(JNK). These inflammatory mediators disrupt the insulin signaling pathway and predispose to insulin
resistance. Therefore, the following question will be thoroughly investigated:
Question 2: Do variations in genes encoding the NF-kappa B, the TNF-α and the JNK,
independently or in synergy, predict an enhanced inflammatory response and subsequent insulin
resistance in Dahl S rats in excessive salt environment?
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Finally, to better understand the combined role of these variations on glucose metabolism, the
following question will be addressed:
Question 3: What are the functional consequences of gene variations on the rate of glucose
delivery, the rate of glucose transport and the rate of glucose phosphorylation in Dahl S rats?
The general hypothesis is that "high-salt diet in combination with defects in candidate genes along
the insulin signaling and inflammatory pathways predicts susceptibility to high salt-induced insulin
resistance in Dahl S rats".
Background
Insulin Resistance
Insulin resistance is defined as an impaired responsive-
ness to both endogenous and exogenous insulin resulting
in high blood glucose levels and compensatory hyperin-
sulinemia [1]. Insulin resistance predicts a constellation
of risk factors that increase the risk of cardiovascular dis-
eases. These include high blood pressure, obesity, type 2
diabetes, elevated triglycerides, and lowered high density
lipoprotein cholesterol (HDL-C) [2,3]. Statistics have
shown that over 30% of Canadian adults have insulin
resistance [4] and that about 50% of salt-sensitive subjects
are insulin resistant [3]. The prevalence of the disease is
expected to increase dramatically over the coming decades
causing an enormous economic burden in both the devel-
oping and developed worlds.
Insulin resistance has major genetic and environmental
factors (such as dietary salt) that are involved in its patho-
genesis [1]. Despite the intense investigations into the
mechanisms of insulin resistance, the contribution of
high-salt to insulin resistance is not yet clear and the genes
responsible for the development of high salt-induced
insulin resistance remain in dispute. Because insulin
resistance phenotype results from the cumulative effects
of several contributing genetic alterations, I chose to focus
on the genetic differences in candidate genes along the
insulin signaling and inflammatory pathways.
Variations in major genes encoding the insulin receptor
substrates -1 and -2 (IRS-1 and -2) and the glucose trans-
porter (GLUTs) proteins correlate with insulin resistance
in humans and animal models of insulin resistance. These
variations act by different mechanisms to disrupt the insu-
lin signaling pathway leading to defects in glucose trans-
port and glucose metabolism.
Multiple lines of evidence suggest a putative role of salt-
induced oxidative stress in the etiology of insulin resist-
ance [5]. Salt-induced oxidative stress triggers a powerful
inflammatory response that disrupts the insulin signaling
pathway and might possibly explain insulin resistance in
genetically susceptible populations [6-8]. Owing to the
fact that high salt-fed Dahl S rats have augmented salt-
induced oxidative stress in most tissues [9-12], and that
oxidative stress generates mediators of inflammation such
as NF-kappa B, TNF-α and JNK, known to disrupt the
insulin signaling pathway, I chose to review the putative
genetic variations in the markedly over-expressed genes
along the inflammatory pathway (NF-kappa B, TNF-α and
JNK) that might be predictive of insulin resistance in Dahl
S rat model. Because the promoter regions of some of the
candidate genes proposed in the current study might pos-
sibly harbor sodium-binding sequences [13,14], any
sequence variations in these putative sodium response
elements might predict protection against insulin resist-
ance in Dahl R rats in excessive salt environments. The
long-term goal is to establish a subset of single nucleotide
polymorphisms (SNPs) that are predictive of insulin
resistance in excessive salt environments.
Why Dahl rats?
Dahl inbred rat strains are classified into salt-sensitive (S)
and salt-resistant (R) based on their blood pressure
responses to high salt diet. Dahl S and R rats share 80% of
their genetic background [15]. Contrary to Dahl R, Dahl S
rats represent a robust model of insulin-resistance syn-
drome on account of their insulin resistance, hypertriglyc-
eridaemia, abdominal obesity and salt-sensitive
hypertension that is exacerbated on dietary sodium intake
[16-19]. Dahl S rats alone had significant insulin resist-
ance, hyperinsulinemia, elevated systolic and diastolic
blood pressures on high salt diet (8% NaCl) for 4 weeks
versus normal salt diet [19,20]. Whole body insulin resist-
ance in Dahl S rats was evidenced by a decrease in glucose
utilization during the hyperinsulinemia-euglycemic
clamp analysis while peripheral insulin resistance in Dahl
S rats was evidenced by a decrease in insulin-stimulated 2
deoxy-glucose uptake by adipocytes and skeletal muscles
obtained from high-salt-fed Dahl S versus Dahl R rats. At
the molecular level, tyrosyl phosphorylation of the insu-
lin receptor, insulin receptor substrates and PI3K, as well
as serine phosphorylation of Akt were all enhanced in
Dahl S versus R rats [19].
Insulin resistance in Dahl S rats does not seem to develop
as a result of an alteration in the insulin receptor number,
affinity, binding parameters, mRNA levels or tissue distri-Cardiovascular Diabetology 2008, 7:19 http://www.cardiab.com/content/7/1/19
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bution in liver, muscle and kidney tissues. These parame-
ters were all comparable in Dahl S and R rats on high or
low salt chow [20]. Moreover, the muscle and adipose tis-
sue glucose transporter protein 4 (GLUT 4) expression
was comparable in soleus muscle and adipose tissue of
Dahl S and R rats on low and high salt diet [19]. Insulin
resistance in Dahl S rats is worsened on high salt diet, and
high salt diet enhances oxidative stress-induced inflam-
matory mediators such as TNF-α, JNK, and NF-kappa B in
Dahl S rats, therefore, high salt-induced oxidative stress
might predict a powerful inflammatory response in Dahl
S  versus  R rats. This powerful inflammatory response
might be caused by genetic differences that enhances the
expression of inflammatory mediators and predispose
Dahl S rats to insulin resistance.
In conclusion, the lack of change in the insulin receptor
number in combination with multiple changes in post
receptor signaling suggests a post receptor defect. The
decreased sensitivity to insulin in Dahl S rats may arise
from a common variant (s) in genes along the insulin sig-
naling and/or inflammatory pathways that triggers a pow-
erful inflammatory response and enhance overt insulin
resistance in Dahl S rats in excessive salt environment
(Figure 1).
Factors along the insulin signaling pathway with 
implications in insulin resistance
Insulin receptor substrates -1 and -2 (IRS-1 and IRS-2)
Insulin effects are predominant in skeletal muscles, liver,
kidney, fat and brain causing increased renal sodium
retention, modulation of transmembrane cation trans-
port, induction of growth promoting effects of vascular
smooth muscle cells and vascular hyperreactivity [21].
Insulin actions are initiated when insulin binds to a high-
affinity heterotetrameric transmembrane protein receptor
that is present in all mammalian cells [22]. This is fol-
lowed by activation of second messengers, also called
docking proteins, such as the insulin receptor substrates-
1, -2, -3 and -4, (IRS-1, -2, -3 and -4) [23-26] via a series
of phosphorylation-dephosphorylation reactions that
result in stimulation of glucose metabolism [27] (Figure
2). While IRS-3 and -4 play a role in cell growth and dif-
ferentiation, IRS-1 and -2 play an important role in glu-
cose metabolism and represent attractive candidate genes
to study in insulin resistance (Tables 1 and 2).
In humans, associations between insulin resistance and
common variants in IRS-1 and -2 have been reported in
several populations [25,28-36], including obese Cauca-
sian children, adults, Asian Indians, Mexicans and Euro-
peans. Mechanisms underlying the contribution of IRS-1
and/or -2 variants to insulin resistance include [37] (Fig-
ure 3): i) altering IRS-1 and/or-2 expression and function,
ii) reduced IRS-1 and/or -2 binding to the insulin recep-
tor, iii) a defect in binding of IRS-1 and/or -2 variant (s)
to the p85 regulatory subunit of the PI3-kinase and a
decrease in PI3-kinase activity. This in turn leads to either
a decreased GLUT4 translocation to the plasma mem-
brane, further reducing glucose transport and glycogen
synthesis, or a significant IRS-1 and/or -2 -induced
decrease in phosphorylation of glycogen synthase kinase-
3 (GSK-3), an enzyme that is important in glycogen syn-
thesis, thus causing reduced glycogen synthesis, iv)
reduced IRS-1 content that is not compensated by a con-
stitutive increase in the IRS-2 protein content. This result
in a reduced insulin-stimulated PI3-kinase activity and a
significant decrease in Akt phosphorylation and activity.
Overall, IRS-1 and/or 2 variants seem to impair the ability
of insulin to activate the IRS/PI3-kinase/Akt/GSK-3 signal-
ing pathway leading to defects in glucose transport, glu-
cose transporters translocation and glycogen synthesis.
IRS-1 and -2 proteins are subjected to phosphorylation on
either tyrosine or serine residues (Figure 4 for structural
organization). IRS-1 and -2 phosphorylation on tyrosine
residues activates IRS proteins to bind to signaling mole-
cules containing SH2 domains, including PI3K [24,38].
Unlike tyrosyl phosphorylation, serine phosphorylation
of IRS proteins attenuated insulin signaling and might
potentially explain an additional mechanism of insulin
resistance in rodents [39] (Figure 5). Owing to the fact
that IRS proteins have three times the number of serine
residues compared to the number of tyrosine residues, the
significance of serine phosphorylation has been signifi-
cantly highlighted. Serine phosphorylation of IRS-1 and
IRS-2 is the main mechanism of suppressing insulin sign-
aling [40,41] in the following ways [40-42]: 1) They can
induce dissociation of IRS proteins from the insulin recep-
tor, 2) hinder tyrosine phosphorylation sites and release
IRS proteins from intracellular complexes that maintain
them in close proximity to the receptor, 3) induce IRS pro-
tein degradation, or 4) turn IRS proteins into inhibitors of
the insulin receptor kinase. Differential serine phosphor-
ylation on IRS-1 and/or-2 has not been studied in Dahl S
versus R rats. Additionally, serine phosphorylation of the
insulin receptor and IRS-1 and -2 [43] is enhanced by
chronic hyperinsulinemia that negatively modulate insu-
lin signaling via activation of TNF-α [43]. Therefore,
chronic hyperinsulinemia in high-salt-fed-Dahl S rats [16]
might as well enhance serine phosphorylation on IRS-1
and/or IRS-2 and explain insulin resistance in Dahl S rats.
Glucose Transporters
The ability to transport glucose across plasma membranes
is mediated by members of the glucose transporter pro-
teins (Table 3). Two families of glucose transporter have
been identified: i) GLUTs: facilitated-diffusion glucose
transporter family also known as 'uniporters,' (GLUT1
through GLUT4), ii) SGLTs: sodium-dependent glucoseCardiovascular Diabetology 2008, 7:19 http://www.cardiab.com/content/7/1/19
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transporter family, also known as 'cotransporters' or 'sym-
porters', transport glucose against its concentration gradi-
ent.
In humans, 23, 38, 2, 1 and 41 mutations have been
reported in GLUT 1, GLUT 2, GLUT 4, GLUT 10, and the
SGLT 1, respectively. These mutations have been associ-
ated with glucose transporters deficiency, lower serum
insulin levels, glucose malabsorption and NIDDM mak-
ing them attractive molecular targets for insulin resistance
and glucose abnormalities [44] (For review, the Human
Gene Mutation Database).
In rats, at least 7 genes are involved in glucose transport.
They are denoted by Slc2a1, Slc2a2, Slc2a3, Slc2a4,
Slc2a8, Slc37a4, Naglt1 (Table 3). Despite the reported
variations in some of the above genes in rats (Table 4), no
further functional studies have been reported so far. Using
the TRANSFAC ® computer program [45], sodium-binding
sequences [13,14] were identified in the promoters of
Slc2a1, Slc2a2, and Slc2a4. As such, association between
high salt and insulin resistance might be through the glu-
cose transporter genes.
Factors along the inflammatory pathways
Inflammation causes a profound change in gene expres-
sion of a large number of inflammatory proteins such as
tumor necrosis factor-alpha (TNF-α), c-Jun Terminal
Kinase (JNK) and nuclear factor-kappa B, (NF-kappa B)
which increases oxygen consumption and produce many
reactive oxygen species (ROS). ROS might as well be trig-
gered by high salt [46]. ROS interfere with normal insulin
signaling and precipitate insulin resistance via a number
of mechanisms including: i) disruption of insulin-
induced IRS-1 and PI3-kinase phosphorylation and cellu-
lar distribution, ii) reduction in GLUT4 expression levels,
or iii) reduction in GLUT4 translocation to the plasma
membrane [47-50]. High salt-fed Dahl S rats had aug-
Mechanism of High Salt-Induced Insulin Resistance in Dahl S rats Figure 1
Mechanism of High Salt-Induced Insulin Resistance in Dahl S rats. Our proposed model of high salt-induced insulin 
resistance in Dahl S rats depends on the combined contributions of high salt and genetic defects along the insulin signaling and 
inflammatory pathways, which in turn predispose Dahl S rats to an augmented inflammatory response and overt insulin resist-
ance.
 Cardiovascular Diabetology 2008, 7:19 http://www.cardiab.com/content/7/1/19
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mented NADPH oxidase activity (oxidative stress inducer)
in cardiac [10], renal [9,11,12], mesenteric microvascular
[9] and brain tissues [51]. Even plasma levels of hydrogen
peroxide (oxidative-stress inducer) in high-salt-fed Dahl S
rats were significantly elevated [9], and the renal antioxi-
dant, superoxide dismutase levels were diminished [9]. As
such, high salt-induced oxidative stress might predict a
powerful inflammatory response in Dahl S versus R rats
because of genetic differences along the inflammatory
pathway that predispose them to perturbations in the
expression of inflammatory genes.
Table 5 includes a list of inflammatory genes (pro- and
anti-inflammatory factors) with potential implications in
insulin resistance. While there are a plethora of genes
associated with inflammation and insulin resistance, I
will focus on a select few TNF-α, JNK, NF-kappa B which
based on the literature are plausible candidates. TNF-α
and JNK are potential mediators of insulin resistance and
are significantly upregulated in high-salt-fed-Dahl S rats
[52,53]. TNF-α and JNK contribute to insulin resistance
by: i) promoting serine phosphorylation of IRS-1 and -2,
ii) formation of a stable complex with IRS-1 and/or IRS-2,
iii) impairing the ability of IRS-1 and -2 to associate with
the insulin receptor and inhibiting insulin-stimulated
tyrosine phosphorylation [54-57].
On the other hand, high salt-fed Dahl S rats possess high
renal nuclear factor-kappa B, NF-kappa B [58], which
might predispose them to insulin resistance. This is
because inhibition of the nuclear factor I-kappa B kinase
B (IKBKB), which is a member of the NF-kappa B, with
salicylates or through targeted gene disruption causes a
dramatic improvement of insulin sensitivity in animal
models of insulin resistance such as ob/ob mice and obese
Zucker fatty rats [59,60]. It also reversed hyperglycemia,
Illustration of the Insulin Pathway and its Potential Contribution to High Salt-Induced Insulin Resistance in Dahl S rats Figure 2
Illustration of the Insulin Pathway and its Potential Contribution to High Salt-Induced Insulin Resistance in 
Dahl S rats. When insulin activates the insulin receptor in vivo, tyrosine phosphorylation of the IRS-1 and IRS-2 activates 
phosphoinositide 3 kinase (PI3K) enzyme, whose activation in turn stimulates the serine phosphorylation of Akt (Protein kinase 
B) [108]. The latter enzyme (PKB) stimulates glucose transport in muscle and adipose tissue through the stimulated transloca-
tion of glucose transporter GLUT4 isoform [109]. PKB also stimulates glycogen synthesis in the liver and muscle, and stimu-
lates lipogenesis in adipose tissue. Existence of variants in genes encoding IRS-1 and/or-2 and glucose transporter proteins 
might impair insulin signaling by suppressing the IRS-1 and/or -2 mRNA levels, protein levels and activity or enhancing serine 
phosphorylation of IRS-1 and -2 resulting in high salt-induced insulin resistance in Dahl S rats.
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hyperinsulinemia, and dyslipidemia in obese rodents. On
the other hand, activation or overexpression of the
nuclear factor I-kappa B (IKBKB) attenuated insulin sign-
aling in cultured cells [60].
As such, common variant (s) in the TNF-α, JNK, or NF-
kappa B might predict a powerful inflammatory reaction
in response to high salt and might possibly explain insu-
lin resistance in Dahl S rats.
Factors implicated in glucose utilization by the cell
Glucose utilization requires three steps: i) delivery of glu-
cose to the plasma membrane, which depends on the
organ's blood flow, capillary recruitment and endothelial
permeability to glucose [61], ii) facilitated transport
across the membrane, which mainly relies on the glucose
transporters numbers and intrinsic activity [61] and iii)
intracellular phosphorylation to glucose-6-phosphate by
a hexokinase cytosolic enzyme (HK) (Figure 6) [62].
In most cases, glucose transport is believed to be the rate
limiting step. However, in conditions of hyperinsuline-
mia like that seen in high-salt-fed Dahl S rats, the rate lim-
iting step may switch to phosphorylation [63,64].
Perturbations in any of these steps might precipitate the
high salt-induced insulin resistance in Dahl S rats. Varia-
tions in the genes proposed in the current study might
affect any of the three steps involved in glucose utiliza-
tion. As for the hexokinase enzyme, increased adrenal
content of norepinephrine and epinephrine in high-salt-
fed Dahl S versus R rats might contribute to a defective hex-
okinase enzymatic activity in Dahl S rats [65]. Epine-
phrine decreases glucose clearance in vivo upon insulin
stimulation [66,67] and suppresses insulin-stimulated
glucose uptake in skeletal muscles [68-70]. This is possi-
bly by: i) stimulating glycogenolysis and accumulating
glucose-6-phosphate [68,71,72] (a strong inhibitor of the
hexokinase enzyme) [73,74]; or ii) by reducing glucose
transport across the membrane [75-77].
Despite comparable muscle and adipose tissue GLUT4
protein levels in Dahl S versus R rats on high and normal
salt diet, Dahl S rats showed reduced glucose uptake by
the muscle [19]. Reduced glucose uptake in high salt-fed-
Dahl S rats might be explained by the high salt-induced
release of epinephrine and norepinephrine that directly
and indirectly inhibit glucose phosphorylation and utili-
zation. Moreover, high salt causes solubilization of the
Table 1: Chromosomal location, genomic and protein sizes of IRS-1 and IRS-2 in rats
Gene Location Size Size of Coding 
region
Justification
Insulin receptor 
substrate 1 (IRS-1)
chr9:81585251–81638071 5365 
bases
3708 bases Low cellular IRS 1 gene and protein expression predict 
insulin resistance and NIDDM.
Impairment of insulin-induced glucose uptake by skeletal 
muscles from high-salt-fed Dahl S rats was neither due to 
changes in the insulin receptor number, mRNA or binding 
affinity, nor due to diminished expression of GLUT4 
protein. Impairment in the insulin signaling pathway might 
possibly be downstream of the insulin receptor and 
upstream of GLUT4, possibly in the IRS-1 and/or IRS-2 
signaling molecules.
Insulin receptor 
substrate 2 (IRS-2)
chr16:18878139–18889441 24234 
bases
3963 bases Ubiquitin-mediated degradation of IRS1 and IRS2 promotes 
insulin resistance. IRS2 dysfunction is critical in the 
development of type 2 diabetes. Insulin was not able to 
suppress gluconeogenic gene expression in primary 
hepatocytes lacking IRS-2, but when IRS-2 signaling was 
reconstituted, these cells recovered this response to 
insulin.
Summary of IRS-1 and -2 genes demonstrating their chromosomal location, respective genomic and coding sequence sizes, and known effects of 
their dysregulation.
Table 2: Previously identified variant (s) in IRS-1 gene in rats
Gene Strain Type Residue SNP Amino Acid
IRS-1 Sprague Dawley
Ref: Brown Norway
Non-synonymous 1160 ENSRNOSNP2552231 T/C
Table showing previously reported IRS-1 variant in Sprague Dawley rats compared to Brown Norway rats. The IRS-1 non-synonymous variant 
caused an amino acid change from Cysteine to Tyrosine. Functional assessment of such variant is yet to be determined [133].Cardiovascular Diabetology 2008, 7:19 http://www.cardiab.com/content/7/1/19
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hexokinase and subsequent inhibition [78], which might
be an additive mechanism in reducing glucose uptake by
peripheral tissues in Dahl S rats. As such, high salt com-
bined with genetic differences in Dahl S versus R rats might
predispose them to insulin resistance.
Hypothesis and objectives
General Hypothesis
High salt diet combined with genetic differences along the
insulin signaling and inflammatory pathways predict a
powerful inflammatory response and susceptibility to
high salt-induced insulin resistance in Dahl S rats.
Specific Hypotheses
  Dahl S rats harbour common variant(s) in the genes
encoding the insulin receptor substrates-1 and/or-2 and/
or the glucose transporter proteins.
  Dahl S rats will display a more powerful inflammatory
response to high salt-induced oxidative stress because of
common variant(s) in the genes encoding the tumor
necrosis factor-alpha, c-jun terminal kinase and the
nuclear factor-kappa B.
  Dahl rats will show reduced glucose delivery, transport
and phosphorylation in liver and kidney tissues com-
pared to Dahl R rats. These differences will be related to
the combined effect of high salt diet and genetic differ-
Contribution of IRS-1 and/or-2 variants to Insulin Resistance Figure 3
Contribution of IRS-1 and/or-2 variants to Insulin Resistance. Mechanisms by which IRS-1 and/or -2 variants contribute 
to insulin resistance include: 1) altering IRS-1 and/or-2 expression and function, 2) reduced IRS-1 and/or -2 binding to the insu-
lin receptor, 3) a defect in binding of IRS-1 and/or -2 variant (s) to the p85 regulatory subunit of the PI3-kinase and a decrease 
in PI3-kinase activity. The latter leads to either a decreased GLUT4 translocation to the plasma membrane, further reducing 
glucose transport and glycogen synthesis, or a significant IRS-1 and/or -2 -induced decrease in phosphorylation of glycogen syn-
thase kinase-3 (GSK-3), an enzyme that is important in glycogen synthesis, thus causing reduced glycogen synthesis, 4) reduced 
IRS-1 content that is not compensated by a constitutive increase in the IRS-2 protein content. This result in a reduced insulin-
stimulated PI3-kinase activity and a significant decrease in Akt phosphorylation and activity.Cardiovascular Diabetology 2008, 7:19 http://www.cardiab.com/content/7/1/19
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ences along the insulin signaling and inflammatory path-
ways.
Objectives
I) To test whether or not Dahl S rats are more susceptible
to high salt-induced insulin-resistance than a matched
Dahl R rats, it is essential to assess and compare genes
encoding the insulin receptor substrates -1 and -2 and
genes encoding the glucose transporter proteins as fol-
lows:
a) Exhaustive candidate gene screening will be done in
Dahl S versus R rats.
b) mRNA, protein and enzyme activities of genes involved
in the insulin signaling pathway (IRS-1, -2, GLUTs) will be
examined on normal, low and high salt diet.
II) To test whether or not Dahl S rats are more susceptible
to high salt-induced inflammation than a matched Dahl
R rats, it is essential to first assess and compare genes
related to the inflammation pathway (NF-kappa B, TNF-
α, JNK) and determine if they differ within or between
populations as follows:
c) Exhaustive candidate gene screening will be done in
Dahl S versus R rats.
d) mRNA, protein and enzyme activities of genes involved
in the insulin signaling pathway (IRS-1, -2, GLUTs) will be
examined on normal, low and high salt diet.
III) To test the combined impact of salt and variations
along the insulin and inflammatory pathways, measure-
ment of glucose delivery to the plasma membranes, glu-
cose transport across the plasma membrane and glucose
phosphorylation will be performed on normal, low and
high salt diet.
IV) To test if these variations identified in objectives I and
II are associated with susceptibility to high salt induced
insulin resistance, haplotype analyses on candidate genes
identified will be of importance.
Methodology
Question 1: Do variations in genes encoding the insulin
receptor substrates -1 and -2 and/or genes encoding the
glucose transporter proteins predict salt-induced insulin
resistance in Dahl S rats?
Aim 1: Determination of polymorphisms in genes encoding for
IRS-1, -2 and the GLUTs proteins
Structural Determinants of Insulin Receptor Substrates Figure 4
Structural Determinants of Insulin Receptor Substrates. IRS-1 and -2 are considerably similar in their general architec-
ture [23,24,38]. They are composed of an NH2-terminal, pleckstrin homology (PH) domain that binds to membrane phosphol-
ipids, a phosphotyrosine binding (PTB) domain located just upstream the PH domain and is involved in the recognition of the 
asparagines-proline-glutamic acid-phosphotyrosine (NPEpY) sequence located in the juxtamembrane region of the insulin 
receptor β subunit, phosphoserine binding domain (PSB), and a less conserved COOH-terminal portion with multiple tyrosine 
phosphorylation motifs that can bind to specific SH2 domain-containing proteins.Cardiovascular Diabetology 2008, 7:19 http://www.cardiab.com/content/7/1/19
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Animals
To identify putative gender differences to susceptibility to
high salt-induced insulin resistance, four-week-old male
and female Dahl salt-sensitive (Dahl S) (n = 200) and salt-
resistant (Dahl R) (n = 200) rats will be purchased from
Harlan Sprague Dawley (Indianapolis, IN) and will be fed
a standard rodent diet containing 0.3% NaCl (normal diet
group) or 8% NaCl (high-salt group) or 0.03% NaCl
(low-salt group) during a 4-week experimental period.
The rats will be housed in a room maintained at constant
humidity (60 ± 5%), temperature (23 ± 1°C), and light
cycle (12 hours: 0700 to 1900). Food and tap water will
be available ad libitum throughout the study. All experi-
mental procedures will be carried out in accordance with
the guidelines of the University of Ottawa Animal Care
Committee for the care and use of laboratory animals. The
rats will be characterized before and after normal, high
and low salt diet in terms of: body weights, food intakes,
blood pressures and plasma parameters (Fasting blood
glucose, fasting plasma insulin). The blood pressure of the
rats will be measured every other day by the tail-cuff
method using a Softron BP-98A automatic sphygmoma-
nometer [19]. Rats will be acclimated to the procedure
daily during the week leading up to study. Blood glucose
and plasma will be assayed using the glucose oxidase and
radioimmunoassay methods, respectively. This will be
performed every week using blood samples obtained from
a tail vein (1 ml) [19]. Measurements of blood pressure,
blood glucose and plasma insulin will continue till the
fourth week post treatment. Prior to sacrificing the rats,
Dahl S versus R rats will be confirmed as insulin resistant
using the hyperinsulinemic-euglycemic clamp procedure
[19].
Genomic DNA isolation and organ collection
Rats will be euthanized 4 weeks post treatment and
genomic DNA will be isolated from white blood cells
using Qiagen Human FlexiGene DNA kit according to the
instructions provided by the manufacturer. 5 mls of
blood/rat are sufficient to produce ample DNA for our
study. Kidney and liver tissues will be collected and imme-
diately flash frozen in liquid nitrogen for mRNA and pro-
tein extraction. Kidney and liver tissues are good
candidate tissues owing to their importance in the patho-
genesis of insulin resistance. Abnormal responses of insu-
lin receptor mRNA levels to high salt intake were reported
in kidneys and livers of animal models of insulin resist-
ance such as the spontaneously hypertensive rats (SHR)
and the fructose-fed rats [79,80].
Search for polymorphisms in genes encoding for IRS-1, -2 and 
glucose transporter proteins
Variants currently identified in genes encoding the IRS-1,
IRS-2 and GLUTs proteins correlate with insulin resist-
ance. In rats (Sprague Dawley), only one non synony-
mous polymorphism has been reported in the IRS-1 gene
so far. However, functional studies are yet to be deter-
mined (Tables 1 and 2). Two independent methods of
genotyping namely DHPLC and sequencing will be com-
bined as was done previously [81-84]. DHPLC offers sen-
sitivity of 95%–100% and specificity of 100% [85], while
sequencing offers sensitivity of 99.7%–100% and specifi-
city of 100% respectively [86]. Combining these highly
sensitive and specific methods of genetic screening will
help eliminate any false positive or false negative results
that might occur with one method of genetic screening.
Sequences will be retrieved from the GenBank [GenBank:
IRS-1 NM_012969;IRS-2: XM_001076309]. Dahl S and R
rats' sequences will be compared to each other and to the
Rattus Norvegicus (Brown Norway rat) sequence readily
available in the Rat Genome Database. Brown Norway rat
sequence will serve as an additional control.
Aim 2: Determination of mRNA and protein expression levels
for genes encoding IRS-1, -2 and glucose transporter proteinsm
Serine phosphorylation in Dahl S rats precipitates insulin  resistance Figure 5
Serine phosphorylation in Dahl S rats precipitates 
insulin resistance. Dahl S rats are postulated in the current 
proposal to have increased serine phosphorylation of insulin 
receptor substrate-1 and/or 2 (IRS-1 and/or-2) on critical 
sites such as Ser 312, 616, 307, and 323. This in turn reduces 
their ability to bind and activate either the insulin receptor or 
the phosphoinositol 3-kinase, resulting in reduced insulin-
stimulated glucose transport activity and other events down-
stream of PI3K.Cardiovascular Diabetology 2008, 7:19 http://www.cardiab.com/content/7/1/19
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RNA Quantification
Kidney, liver and brain tissues will be utilized for total
RNA extraction using the Qiagen RNeasy Mini Kit [87-89].
Fold differences in mRNA levels for genes encoding IRS-1,
-2 and the GLUTs glucose transporter proteins will be
obtained using quantitative RT-PCR [90].
Protein Quantification
ReadyPrep™ Protein Extraction Kit (Signal), from Bio-Rad,
will be utilized to extract total protein from the kidney,
liver and brain tissues of Dahl rats after 4 weeks. The avail-
ability of an antiserum specific for the IRS-1 and -2 and
GLUT proteins (Upstate Biotechnology Inc. Lake Placid,
NY) will allow us to probe for these proteins in kidney,
liver and brain cell homogenates.
Aim 3: Are IRS-1 and -2 differentially phosphorylated on serine
residues
Variations in genes encoding IRS-1 or -2 might be at the
level of DNA (genetic variants) or at the level of serine
phosphorylation. In order to examine differential serine
phosphorylation of IRS-1 and -2 in Dahl S, versus R rats,
anti-IRS-1 phosphoserine antibody will be utilized to
probe kidney, liver and brain samples from low, regular
and high salt diet. Fold increase or decrease in IRS-1 and -
2 serine phosphorylation in Dahl S rats post dietary treat-
ment will be compared with control Dahl R rats.
Ogihara et al., in 2002 reported an enhanced tyrosine
phosphorylation of the insulin receptor, insulin receptor
substrates, PI3K activation and serine phosphorylation of
Akt in Dahl S versus R rats [19]. However, there were some
limitations to the procedures they used. First, Dahl rats
were fasted for 12 hours prior to the experiment assessing
IRS-1 and -2 phosphorylation. Fasting is reported to
enhance insulin-induced IRS-1 and IRS-2 tyrosine phos-
phorylation and association with PI3-kinase in liver and
muscle of animal models of insulin resistance (streptozo-
Table 3: Chromosomal location, tissue distribution and transcript information of genes encoding glucose transporters
Gene 
Symbol
Gene name Chromosomal 
Location
Tissue Distribution Function Transcript 
Information
Slc2a1 facilitated glucose transporter 
member 1 (Glucose transporter 
type 1) (GLUT-1)
chr5:139690804–13
9719021
All tissues (abundant in 
brain and 
erythrocytes)
Basal uptake Exons: 10
Transcript length: 
2,365 bps
Protein length: 492 
residues
Slc2a2 solute carrier family 2, facilitated 
glucose transporter member 2 
(Glucose transporter type 2) 
(GLUT-2)
chr2:116036427–11
6065870
Liver, pancreatic islet 
cells, retina
Glucose sensing Exons: 12
Transcript length: 
2,578 bps
Protein length: 524 
residues
Slc2a3 solute carrier family 2, facilitated 
glucose transporter member 3 
(Glucose transporter type 3) 
(GLUT-3)
chr4:159210019–15
9221248
All tissues specially the 
brain
Supplements GLUT1 in 
tissues with high energy 
demand
Exons: 9
Transcript length: 
1,467 bps
Protein length: 488 
residues
Slc2a4 solute carrier family 2, facilitated 
glucose transporter member 4 
(Glucose transporter type 4) 
(GLUT-4).
chr10:56,786,705–5
6,792,209.
Muscle, fat, heart Insulin responsive Exons: 11
Transcript length: 
2,506 bps
Protein length: 509 
residues
Slc2a8 solute carrier family 2, facilitated 
glucose transporter member 8 
(Glucose transporter type 8) 
(GLUT-8)
chr3:11962578–119
72099
hippocampal neurons, 
testis, whole brain
Exons: 10
Transcript length: 
2,087 bps
Protein length: 478 
residues
Naglt1 Sodium dependant glucose 
transporter 1
chr20:44,147,331–4
4,176,308.
In all cells Exons: 4
Transcript length: 
1,455 bps
Protein length: 484 
residues
Slc37a4 solute carrier family 37 (glucose-
6-phosphate transporter), 
member 4
chr 8: 
47,363,896–47,369,
981.
Liver, Adipocytes Exons: 9
Transcript length: 
2,080 bps
Protein length: 429 
residuesCardiovascular Diabetology 2008, 7:19 http://www.cardiab.com/content/7/1/19
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tocin treated rats) [91]. Secondly, the authors injected
insulin in the portal vein of rats once after which immedi-
ately they harvested livers and hindlimb muscles for
measuring the IRS-1 and -2 levels and tyrosyl phosphor-
ylation. Co-immunoprecipitation experiments of IRS-1
and -2 were done in triplicates. Regardless of the fact that
the authors has done the insulin injection once and then
repeated the immunoblotting experiment three times on
the harvested liver and hindlimbs of Dahl rats, it is docu-
mented that within 1 minute of acute insulin stimulation,
enhancement of the insulin signaling pathway and aug-
mentation of IRS content and tyrosyl phosphorylation
together with PI3K activation occur [92,93]. On the con-
trary, chronic effects of insulin have been shown to
enhance IRS-1 serine phosphorylation preventing its sub-
sequent tyrosine phosphorylation [94]. Therefore fasting
and acute insulin injection in Dahl S rats (a model of insu-
lin resistance) were additive in enhancing the insulin sig-
naling pathway. It would have been more proper to show
the impact of chronic insulin stimulation in high-salt-fed
Dahl S rats without fasting or acute insulin stimulation,
both of which might have misrepresented the actual
defects in insulin signaling in Dahl S rats. Therefore, I pro-
pose to use the same procedure adopted by Sechi et .al.,
1997, where the animals were neither fasted nor injected
insulin prior to the experiment [95].
It is also possible that even in the presence of enhanced
IRS-1 and/or -2 tyrosyl phosphorylation in Dahl S rats
that enhanced serine phosphorylation in Dahl S rats
would be the mechanism behind high salt-induced insu-
lin resistance in this model. Serine phosphorylation might
induce some conformational change that does not affect
tyrosine phosphorylation but inhibits the insulin signal-
ing pathway, via rapid tyrosyl dephosphorylation and
deactivation or by acting as inhibitors to the insulin recep-
tor kinase [40-42].
High salt might as well exert an additional inhibitory
effect on IRS-1  and  -2, possibly by interacting with a
sodium-binding sequence [13,14] on the IRS-1 and/or -2
genes to suppress their mRNA and/or protein levels in
Dahl S versus R rats. I was able to locate a sodium response
element in the proximal promoters of IRS-1 and IRS-2
genes. As such, associations between high salt intake and
insulin resistance might exist through the IRS-1 and/or -2
genes.
Aim 4: Determination of the impact of any variant/variants on
the activity of IRS-1 and IRS-2, GLUTs
To test the impact of identified 5' flanking region vari-
ant(s) on the activity of IRS-1, IRS-2 and GLUTs, reporter
genes can be used to assay for the activity of the promotor
in a cell. The reporter gene (e.g. luciferase or GFP) is
placed under the control of the IRS-1 or IRS-2 or GLUT
promotor and the reporter gene product's activity is quan-
titatively measured. The results are normally reported rel-
ative to the activity under a "consensus" promoter known
to induce strong gene expression. For variants identified
in the coding region, we will assess the impact of such var-
iant in altering the resultant amino acid sequence. The
IRS-1  and  IRS-2  constructs will be prepared using the
same techniques we previously optimized [87,88,90].
Briefly, RT-PCR will be employed to amplify full length
genes with the variant (s) identified from Dahl S rats'
Table 4: Previously reported variant (s) in genes encoding glucose transporter proteins
Gene Strain Type Residue SNP Amino Acid
Slc2a1 Sprague Dawley
Ref: Brown Norway
Synonymous 383 ENSRNOSNP1925604 C/T
Slc2a2 Sprague Dawley
Ref: Brown Norway
Non-synonymous 475 ENSRNOSNP1165255 A/G
Sprague Dawley
Ref: Brown Norway
Non-synonymous 512 ENSRNOSNP1165256 G/A
Sprague Dawley
Ref: Brown Norway
Synonymous 520 ENSRNOSNP1165257 T/A
Slc2a3 Sprague Dawley
Ref: Brown Norway
Non-synonymous 50 rs8172435 G/C
Sprague Dawley
Ref: Brown Norway
Synonymous 147 rs8160316 A/C
Sprague Dawley
Ref: Brown Norway
Non-synonymous 442 rs8172437 A/G
Sprague Dawley
Ref: Brown Norway
Non-synonymous 465 rs8172438 C/G
Naglt1 Sprague Dawley
Ref: Brown Norway
Non-synonymous 166 ENSRNOSNP1513056 C/A
Previously reported variants in the glucose transporters in the Sprague Dawley rat. The reference strain was the Brown Norway rat [133].Cardiovascular Diabetology 2008, 7:19 http://www.cardiab.com/content/7/1/19
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Table 5: List of Major Candidate Genes Involved in the Inflammation Pathway
Gene Symbol Gene Name Chromosomal 
Location
Transcript information Justification
TNF-α tumor necrosis factor 
receptor superfamily
chr3:156092602–156107
426
Exons: 9
Transcript length: 
1,247 bps
Protein length: 289 
residues
TNF-α, a potential mediator of 
insulin resistance, promotes 
serine phosphorylation of IRS-
1 and -2, impairs the ability of 
IRS-1 and -2 to associate with 
the insulin receptor and 
inhibits insulin-stimulated 
tyrosine phosphorylation 
[54–56]. TNF-α is upregulated 
in Dahl S rats [52].
NF-kappa-B-
activating protein
Nuclear factor kappa-B-
activating protein
chr X: 
7,762,299–7,781,765.
Exons: 9
Transcript length: 
1,248 bps
Protein length: 415 
residues
Renal NF-{kappa}B is 
significantly upregulated in 
high-salt-fed Dahl S rats [58].
NF-IKBKB Nuclear factor kappa-B 
kinase subunit beta
chr16: 
73,805,082–73,858,088.
Exons: 21
Transcript length: 
3,022 bps
Protein length: 757 
residues
Inhibition of IKBKB with 
salicylates or through targeted 
gene disruption causes a 
dramatic improvement of 
insulin sensitivity in animal 
models of insulin resistance 
such as ob/ob mice and obese 
Zucker fatty rats [59,60].
IL1β Interleukin-1β receptor 
accessory protein 
precursor
chr11: 
76,092,840–76,222,495.
Exons: 11
Transcript length: 
1,862 bps
Protein length: 570 
residues
IL1β activates jnk which is 
upregulated in high-salt-fed 
Dahl S rats [57].
IL17d interleukin 17D chr 15: 
36,566,307–36,583,168.
Exons: 9
Transcript length: 621 
bps
Protein length: 206 
residues
IL-17 D, a proinflammatory 
cytokine that enhances T cell 
priming and stimulates the 
production of proinflammatory 
molecules such as IL-1, IL-6, 
TNF-alpha, NOS-2, and 
chemokines resulting in 
inflammation.
IL10 Interleukin-10 precursor 
(IL-10) (Cytokine 
synthesis inhibitory 
factor) (CSIF).
chr 13: 43.95m Exons: 5
Transcript length: 
1,289 bps
Protein length: 178 
residues
IL-10, also known as human 
cytokine synthesis inhibitory 
factor (CSIF), is an anti-
inflammatory cytokine. This 
cytokine can block NF-kappa B 
activity, and is involved in the 
regulation of the JAK-STAT 
signaling pathway. It is capable 
of inhibiting synthesis of pro-
inflammatory cytokines like 
Interferon-gamma, IL-2, IL-3, 
TNFα and GM-CSF made by 
cells such as macrophages and 
the Type 1 T helper cells.
Crp C-reactive protein 
precursor
chr 13: 
88,674,743–88,715,585.
Exons: 2
Transcript length: 
1,655 bps
Protein length: 230 
residues
Insulin resistance and C-
reactive protein (CRP) levels 
are strongly correlated in 
adults [110].
Ratsg2 Selenoprotein S (VCP-
interacting membrane 
protein) (Sg2).
chr 1: 
120,509,128–120,518,32
2.
Exons: 6
Transcript length: 573 
bps
Protein length: 190 
residues
In humans, polymorphisms in 
the encoded plama membrane 
selenoprotein (SEPS1, or SELS 
gene) correlate to diabetes 
mellitus and coronary heart 
diseases. The selenoprotein 
regulate red-ox balance and 
clear cells of misfolded 
proteins. Gene polymorphisms 
result in accumulation of these 
proteins even higher under cell 
stress. Carriers have higher 
IL1, -6, -10, and TNF [111].Cardiovascular Diabetology 2008, 7:19 http://www.cardiab.com/content/7/1/19
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Ptpn22_predicted protein tyrosine 
phosphatase, non-
receptor type 22 
(lymphoid) (predicted)
chr 2: 
199,083,234–199,132,76
1
Exons: 22
Transcript length: 
2,476 bps
Protein length: 803 
residues
Tyrosine phosphatase gene 
(PTPN22) prevents 
spontaneous T-cell activation. 
In humans, mutations 
(C1858T, R620W) was 
associated with type 1 diabetes 
[112–114].
Crhr1 Corticotropin-releasing 
factor receptor 1 
precursor (CRF-R) 
(CRF1) (Corticotropin-
releasing hormone 
receptor 1) (CRH-R 1).
chr 10: 93.31 m Exons: 12
Transcript length: 
1,218 bps
Protein length: 405 
residues
Crhr1 is required for a normal 
chromaffin cell structure and 
function and deletion of this 
gene is associated with a 
significant impairment of 
epinephrine release.
IL6 Interleukin-6 precursor chr 4: 456,799–461,376. Exons: 6
Transcript length: 
1,042 bps
Protein n length: 210 
residues
Impaired glucose tolerance is 
associated with increased 
serum concentrations of 
interleukin 6 [115].
IL15 Interleukin-15 precursor. chr 19: 
27,482,376–27,499,255.
Exons: 6
Transcript length: 768 
bps
Protein length: 161 
residues
IL-15 increases insulin 
sensitivity therefore increasing 
glucose transport and 
utilization in muscles [116].
IL18 interleukin 18 chr 9: 
39,676,026–39,698,748.
Exons: 10
Transcript length: 
1,884 bps
Protein length: 604 
residues
Elevated plasma interleukin-18 
is a marker of insulin-
resistance in type 2 diabetic 
and non-diabetic humans 
[117,118].
Map2k7 Dual specificity mitogen-
activated protein kinase 
kinase 7
chr 12: 
1,543,467–1,552,353.
Exons: 13
Transcript length: 
1,407 bps
Protein length: 468 
residues
MAP2K7 selectively activates 
the JNKs which suppresses 
insulin signaling [57].
Mapk6 Mitogen-activated protein 
kinase 6 or (Extracellular 
signal-regulated kinase 3) 
(ERK-3) (p55-MAPK).
chr 8: 
80,212,726–80,236,362
Exons: 6
Transcript length: 
4,180 bps
Protein length: 720 
residues
ERK3 associates with MAP2 
and is involved in glucose-
induced insulin secretion 
[119].
Map4k4 Mitogen-activated protein 
kinase 4-isoform4
chr 9: 
39,070,845–39,211,446.
Exons: 34
Transcript length: 
4,401 bps Translation 
length: 1,232 residues
Map4k4 gene silencing in 
human skeletal muscle 
prevents tumor necrosis 
factor-alpha-induced insulin 
resistance [120].
Map2k1 Dual specificity mitogen-
activated protein kinase 
kinase 1 or (MAP kinase 
kinase 1) (MAPKK 1) 
(ERK activator kinase 1) 
(MAPK/ERK kinase 1) 
(MEK1).
chr 8: 
68,379,077–68,451,583.
Exons: 11
Transcript length: 
2,120 bps
Protein length: 393 
residues
MAP2K1 restored insulin 
action on glucose uptake by 
cells [120,121].
Jnk C-Jun amino terminal 
kinase
chr 3: 76.78 m Exons: 12
Transcript length: 
2,992 bps
Protein length: 699 
residues
JnK is activated by TNF-α and 
IL-β. Jnk forms a stable 
complex with IRS-1 and 
phosphorylates Ser307 that 
inhibits insulin stimulated 
tyrosine phosphorylation of 
IRS-1 [57].
Cx3cr1 CX3C chemokine 
receptor 1
chr 8: 125.03 m Exons: 2
Transcript length: 
1,326 bps
Protein length: 354 
residues
Modulators of CX3CR1 can be 
used to treat diabetes, as well 
as diagnose diabetes by 
measuring the levels of 
CX3CR1 in a patient (US 
patents 2006).
Ccr3 C-C chemokine receptor 
type 3
chr 8: 128.76 m Exons: 2
Transcript length: 
1,315 bps
Protein length: 359 
residues
CCL3was reported to be 
increased in obese mice and to 
contribute to insulin resistance 
and macrophage recruitment 
[122].
Table 5: List of Major Candidate Genes Involved in the Inflammation Pathway (Continued)Cardiovascular Diabetology 2008, 7:19 http://www.cardiab.com/content/7/1/19
Page 14 of 21
(page number not for citation purposes)
Ccr2 C-C chemokine receptor 
type 2
chr 8: 128.89 m Exons: 1
Transcript length: 
1,122 bps
Protein length: 373 
residues
CCR2 influences the 
development of obesity and 
associated adipose tissue 
inflammation and systemic 
insulin resistance [123].
Ccr5 C-C chemokine receptor 
type 5
chr 8: 128.91 m Exons: 2
Transcript length: 
2,495 bps
Protein length: 354 
residues
CCR5 polymorphisms in 
children with insulin-
dependent diabetes mellitus 
[124].
Nox3 NADPH oxidase 3 chr 1: 38.64 m Exons: 14
Transcript length: 
1,761 bps
Protein length: 586 
residues
NOX3, a ROS generating 
NADPH oxidase, plays an 
integral role in insulin-induced 
signal transmission [125].
Nox4 NADPH oxidase 4 chr 1: 143.42 m Exons: 18
Transcript length: 
2,176 bps
Protein length: 578 
residues
The NAD(P)H Oxidase 
Homolog Nox4 Modulates 
Insulin-Stimulated Generation 
of H2O2 and Plays an Integral 
Role in Insulin Signal 
Transduction [126].
Ptgs2 Prostaglandin G/H 
synthase 2 precursor 
(Cyclooxygenase-2) 
(COX-2) (Prostaglandin 
H2 synthase 2) (PGH 
synthase 2) (PGHS-2) 
(PHS II).
chr 13: 
64,427,282–64,432,982.
Exons: 10
Transcript length: 
1,825 bps
Protein length: 604 
residues
PTGS2 generates 
prostaglandins, which 
negatively modulate glucose-
stimulated insulin secretion, 
and functions as a mediator of 
the inflammatory response 
[127].
Alox5 Arachidonate 5-
lipoxygenase (5-
lipoxygenase) (5-LO)
chr 4: 152.61 m Exons: 14
Transcript length: 
2,450 bps
Protein length: 674 
residues
The epidemiologic data suggest 
that subjects with two variant 
alleles will have greater 
ALOX5 gene expression, 
greater production of 
arachidonic acid-derived 
leukotrienes and a more 
"proinflammatory phenotype 
than subjects with two 
common alleles.
Alox5ap Arachidonate 5-
lipoxygenase-activating 
protein (FLAP) (MK-886-
binding protein).
chr 12: 6.25 m Exons: 5
Transcript length: 937 
bps
Protein length: 161 
residues
ALOX5AP expression, but not 
gene haplotypes, is associated 
with obesity and insulin 
resistance [128].
Nos3 Nitric-oxide synthase, 
endothelial (NOSIII) 
(Endothelial NOS) 
(eNOS)
chr 4: 6.16 m Exons: 26
Transcript length: 
3,953 bps
Protein length: 1,202 
residues
The (-)786T-C mutation of the 
eNOS gene is associated with 
insulin resistance in both 
Japanese non-diabetic subjects 
and Type II diabetic patients 
[129]
Nos2 Nitric oxide synthase, 
inducible (NOS type II) 
(Inducible NO synthase) 
(Inducible NOS) (iNOS)
chr 10: 65.04 m Exons: 27
Transcript length: 
4,106 bps
Protein length: 1,147 
residues
obese Nos2 -/- mice exhibited 
improved glucose tolerance, 
normal insulin sensitivity in vivo 
and normal insulin-stimulated 
glucose uptake in muscles 
[130].
Cpr NADPH-cytochrome 
P450 reductase (CPR) 
(P450R).
chr 12: 22.08 m Exons: 16
Transcript length: 
2,438 bps
Protein length: 678 
residues
NADPH-cytochrome P450 
reductase (CPR) plays a role in 
type II diabetes [131]
Pla2g1b Phospholipase A2 
precursor
chr 12: 42.41 m Exons: 4
Transcript length: 543 
bps
Protein length: 146 
residues
Mice with targeted inactivation 
of the group 1B phospholipase 
A [2] (Pla2glb) gene displayed 
lower postprandial glycemia 
than that observed in wild-type 
mice after being fed a glucose-
rich meal [132].
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cDNA. Full length constructs from Dahl R rats' cDNA will
be used as a control. Representative kidney and liver cell
lines such as COS-7 cells and HepG2 cells respectively will
be transfected with either the mutant or the correspond-
ing wildtype as control. mRNA and protein levels will be
further assessed by QRT-PCR and western blotting respec-
tively to test the impact of such variant (s) in altering the
mRNA and/or protein levels. Co-transfection studies will
be performed to investigate the impact of combined vari-
ants in altering the mRNA and protein expression of IRS-
1 and IRS-2, and whether a synergistic or an inhibitory
response will be the outcome of such combination.
Question 2: What genes, independently or in synergy,
along the inflammatory pathway are predictive of high
salt-induced insulin resistance in Dahl S rats?
Aim 1: Determination of expression levels of candidate genes
along the inflammatory pathway
The somewhat disappointing results of linkage studies for
multi-factorial phenotypes coupled with the theory that
an individual phenotype results from the cumulative
effects of several contributing loci, has lead genetic inves-
tigators back to the study of candidate genes in case-con-
trol designs [96]. Identification of such candidates has
become increasingly rapid with modern molecular meth-
ods such as microarrays. High-throughput microarray
Steps Involved in Glucose Utilization Figure 6
Steps Involved in Glucose Utilization. Schematic representation of the three steps involved in glucose utilization. In most 
cases, glucose transport is believed to be the rate limiting step. However, in conditions of hyperinsulinemia like that seen in 
high-salt-fed Dahl S rats, the rate limiting step may switch to phosphorylation [63,64]. Pertubations in any of these steps might 
precipitate the high salt-induced insulin resistance in Dahl S rats.Cardiovascular Diabetology 2008, 7:19 http://www.cardiab.com/content/7/1/19
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platforms are capable of measuring the expression of
thousands of genes simultaneously allowing for the iden-
tification of genes that are differentially expressed in tis-
sues from various individuals. Despite the recognized
limitations (variation in expression resulting from poly-
morphism, environmental variation, or RNA quality) they
can potentially reveal novel molecular mechanisms con-
tributing to phenotypes as well as uncover alternate can-
didate genes derived without previous bias. As such,
cDNA microarrays offers:i) detection of previously unsus-
pected genes with a likely role in inflammation, ii) follow-
up of much over and underexpresion of gene populations
compared with controls, iii) identification of phenotypi-
cally-associated specific patterns of gene expression.
Before pursuing genes along the inflammatory pathway
(TNF-α, JNK and NF-kappa B ) (Table 5), fold differences
in mRNA levels will be obtained in microarray experi-
ments and confirmed using quantitative RT-PCR. Hence
haplotype analyses will only be performed on those genes
whose mRNA expression patterns, protein levels or activ-
ity, significantly differ within or between the Dahl S and R
population pre and post-high salt diet. Despite the high
cost associated with the use of microarrays, they will ena-
ble us to identify potential inflammatory genes whose
expression might be altered by diet in Dahl S versus R rats,
and might likely influence insulin resistance in Dahl rats.
Microarrays will also eliminate the most time consuming
and expensive component of a future candidate gene
study, and will simply direct our genetic focus to potential
and differentially expressed candidate genes.
Aim 2: Searching for polymorphisms in candidate genes along
the inflammatory pathway (Methodology Section-Question 1
Aim 1).
Aim 3: Determination of the impact of any variant/variants on
the activity of TNF-α, JNK and NF-kappa B (Methodology Sec-
tion-Question 1 Aim 4)
Aim 4: Construction of SNPs haplotypes
For haplotype construction, previously reported polymor-
phisms (mostly SNPs) will be identified for each candi-
date gene by a careful screening of available
polymorphism databases. This approach is enhanced by
the completion of the rat genome sequence by the Rat
Genome Sequencing Project Consortium and the rapidly
growing databases of rat polymorphisms, including those
of The Rat SNP Consortium. Furthermore, in order to
identify potential mutations and/or new polymorphisms,
a systematic screening of the proximal promoters (2500
bp) will be performed. In order to exhaustively explore
genetic variations, it will be essential to combine DHPLC
and sequencing (ABI 310/3100 sequencers) screenings
(Methodology section Question 1). DNA from rats in
each population group will be used to define the haplo-
types in the genes associated with differing expression
post-dietary tratemnt. Haplotypes will be inferred using
the PHASE software package [97]. Highly efficient geno-
typing techniques, depending on the selected variant, will
be used to genotype the populations (Denaturing High
Performance Liquid Chromatography (DHPLC), Allele
Specific Oligonucleoprobe (ASO), SNaPshot™ Multiplex
System).
Question 3: What are the functional consequences of gene
variations on the rate of glucose delivery to the cells, the
rate of glucose transport and the rate that glucose is phos-
phorylated within these same cells?
Aim: Determination of glucose delivery to cell membrane,
glucose transport across cell membranes and glucose
phosphorylation.
Measurement of interstitial glucose is relevant as it is the
substrate for glucose transport. This will be performed by
microdialysis as previously described [98-100]. Measure-
ment of intracellular glucose will be predictive of the effi-
ciency of glucose transport across cell membranes. This
can be done by radioactive glucose analogues that are
either not transported or not phosphorylated to calculate
glucose concentration localized to each side of the mem-
brane [101-105]. To assess perturbations in glucose phos-
phorylation, measuring the hexokinase enzyme activity
will be performed in kidney, liver and brain tissues of
Dahl rats. This will be done as previously described
[106,107].
Anticipated results
On high salt diet, IRS-1 and/or -2 mRNA and protein lev-
els will be diminished in Dahl S versus R rats (figure 7). No
changes are expected in IRS-1 and/or -2 mRNA and pro-
tein levels in Dahl S rats on normal salt diet, or in Dahl R
rats on any of the dietary treatments (low, normal and
high salt diet). On low salt diet, IRS-1 and/or -2 mRNA
and protein levels in Dahl S rats might not change or on
the contrary they might increase because of the reduced
levels of sodium acting on the salt-response element in
the promoter region of IRS-1 and/or -2. It is postulated in
the current hypothesis that this sodium-binding sequence
will be a salt-responsive element that will possess an
inhibitory effect on IRS-1 and/or -2. The less salt the
greater the IRS-1 and/or -2 mRNA and protein levels. Ser-
ine phosphorylation is expected to be enhanced in Dahl S
versus R rats, possibly by the higher insulin levels in Dahl
S rats.
On the other hand, variants in the genes encoding the
GLUT proteins in Dahl S rats, combined with high saltCardiovascular Diabetology 2008, 7:19 http://www.cardiab.com/content/7/1/19
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will decrease the activity of GLUT proteins and decrease
glucose transport in Dahl S rats (figure 8).
Perspectives
The present hypothesis together with the proposed exper-
imental approach to test it will provide the first compre-
hensive evaluation of the sequence differences as well as
serine phosphorylation patterns of genes along the insu-
lin signaling pathway (IRS-1 and -2 genes and GLUTs) in
Dahl S and R rats, and the first comprehensive assessment
of the impact of any identified variant (s) on their activity,
mRNA and protein levels in Dahl S and R rats. It will also
be the first study using microarrays to identify which
genes along the inflammatory pathway in Dahl S versus R
rats show differing expression profiles pre and 4-weeks
post salt overload, and if successful it will be the first to
identify whether or not combined genetic differences
along the insulin signaling and inflammatory pathways
account for the variance in response to salt intake in or
between Dahl-rat groups. Genetic factors contributing to
high salt-induced insulin resistance in salt-sensitive Dahl
rats will be identified, and the synergistic impact of salt
diet will be described. Upon completion of the proposed
research project, a sub-set of SNPs in genes encoding the
IRS-1, IRS-2, glucose transporters, pro- and anti-inflam-
matory genes will be identified in Dahl S rats that might
likely influence their susceptibility to insulin resistance
and salt-sensitive hypertension.
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Anticipated Results Figure 7
Anticipated Results. Summary of Expected Results in the Proposed Studies: On high salt diet, IRS-1 and/or -2 mRNA and 
protein levels will be diminished in Dahl S versus R rats. No changes are anticipated in IRS-1 and/or -2 mRNA and protein levels 
in Dahl S rats on normal salt diet, or in Dahl R rats on any of the dietary treatments (low, normal and high salt diet). On low 
salt diet, IRS-1 and/or -2 mRNA and protein levels in Dahl S rats might not change or on the contrary they might increase 
because of the reduced levels of sodium acting on the salt-response element in the promoter region of IRS-1 and/or -2. It is 
postulated in the present hypothesis that this salt-responsive element possesses an inhibitory effect on IRS-1 and/or -2. The 
less salt the greater the IRS-1 and/or -2 mRNA and protein levels. Serine phosphorylation is expected to be enhanced in Dahl 
S versus R rats, possibly by the higher insulin levels in Dahl S rats.
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